CD274 and melanoma: Since immunotherapy has only benefited a subset of patients due to the heterogeneity of the patients’ microbiome11,45, the immune checkpoint inhibitor PD-L1 against melanoma growth and metastasis was used to further test our hypothesis that PNP could enhance anti-PD-L1 based immunotherapy mediated by PNP targeting of the gut microbiome.